Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Acquired by Bridgewater Associates LP

Bridgewater Associates LP increased its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 69.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 192,035 shares of the specialty pharmaceutical company's stock after purchasing an additional 79,036 shares during the period. Bridgewater Associates LP owned approximately 0.32% of Jazz Pharmaceuticals worth $23,649,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of JAZZ. HighTower Advisors LLC raised its holdings in Jazz Pharmaceuticals by 37.2% during the 3rd quarter. HighTower Advisors LLC now owns 7,594 shares of the specialty pharmaceutical company's stock valued at $851,000 after buying an additional 2,060 shares during the period. Public Employees Retirement System of Ohio bought a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter worth about $2,491,000. Barclays PLC boosted its stake in shares of Jazz Pharmaceuticals by 19.1% during the 3rd quarter. Barclays PLC now owns 39,210 shares of the specialty pharmaceutical company's stock worth $4,369,000 after purchasing an additional 6,289 shares during the period. Coldstream Capital Management Inc. raised its position in Jazz Pharmaceuticals by 7.7% in the 3rd quarter. Coldstream Capital Management Inc. now owns 2,300 shares of the specialty pharmaceutical company's stock worth $259,000 after purchasing an additional 165 shares during the period. Finally, Sanctuary Advisors LLC lifted its stake in Jazz Pharmaceuticals by 502.8% in the third quarter. Sanctuary Advisors LLC now owns 11,754 shares of the specialty pharmaceutical company's stock worth $1,310,000 after purchasing an additional 9,804 shares during the last quarter. Institutional investors own 89.14% of the company's stock.

Wall Street Analyst Weigh In

JAZZ has been the subject of a number of research analyst reports. Barclays reissued an "overweight" rating and set a $200.00 price target (up from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. Morgan Stanley reaffirmed an "overweight" rating and issued a $183.00 price target (up previously from $175.00) on shares of Jazz Pharmaceuticals in a research note on Friday, March 7th. JPMorgan Chase & Co. raised their target price on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Wells Fargo & Company raised Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and increased their price objective for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. Finally, UBS Group raised Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and increased their price target for the stock from $145.00 to $179.00 in a research report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $187.71.

Insiders Place Their Bets

In related news, CAO Patricia Carr sold 4,813 shares of the company's stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $144.42, for a total value of $695,093.46. Following the transaction, the chief accounting officer now directly owns 8,237 shares of the company's stock, valued at $1,189,587.54. This represents a 36.88 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $122.31, for a total value of $183,465.00. Following the sale, the chief executive officer now directly owns 439,744 shares of the company's stock, valued at approximately $53,785,088.64. This represents a 0.34 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 28,736 shares of company stock valued at $4,023,305. 4.20% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Stock Down 3.2 %

Shares of Jazz Pharmaceuticals stock traded down $3.27 during trading on Monday, reaching $99.51. The company's stock had a trading volume of 96,286 shares, compared to its average volume of 786,791. The company has a 50-day simple moving average of $127.60 and a two-hundred day simple moving average of $122.50. Jazz Pharmaceuticals plc has a 1-year low of $95.49 and a 1-year high of $148.06. The company has a market cap of $6.04 billion, a price-to-earnings ratio of 14.02, a P/E/G ratio of 1.04 and a beta of 0.42. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.